Other
Other Comprehensive Income (Loss)
Alnylam Pharmaceuticals Other Comprehensive Income (Loss) increased by 77.7% to $201.19M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1046.8%, from -$21.25M to $201.19M. Over 4 years (FY 2021 to FY 2025), Other Comprehensive Income (Loss) shows an upward trend with a -23.2% CAGR.
Analysis
StatementIncome Statement
SectionOther
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID:
tmusz_other_comprehensive_income_lossHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$188.92M | -$202.66M | -$257.49M | -$245.15M | -$281.56M | -$407.48M | -$208.36M | -$168.57M | -$273.98M | $152.49M | -$128.91M | -$69.55M | -$24.54M | -$101.76M | -$93.46M | -$21.25M | -$58.71M | $259.26M | $113.22M | $201.19M |
| QoQ Change | — | -7.3% | -27.1% | +4.8% | -14.9% | -44.7% | +48.9% | +19.1% | -62.5% | +155.7% | -184.5% | +46.0% | +64.7% | -314.7% | +8.2% | +77.3% | -176.3% | +541.6% | -56.3% | +77.7% |
| YoY Change | — | — | — | — | -49.0% | -101.1% | +19.1% | +31.2% | +2.7% | +137.4% | +38.1% | +58.7% | +91.0% | -166.7% | +27.5% | +69.4% | -139.3% | +354.8% | +221.2% | >999% |
Range-$407.48M – $259.26M
CAGR+1.3%
Avg YoY Growth+102.6%
Median YoY Growth+34.7%
Other Comprehensive Income (Loss) at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's other comprehensive income (loss)?
- Alnylam Pharmaceuticals (ALNY) reported other comprehensive income (loss) of $201.19M in Q1 2026.
- How has Alnylam Pharmaceuticals's other comprehensive income (loss) changed year-over-year?
- Alnylam Pharmaceuticals's other comprehensive income (loss) increased by 1046.8% year-over-year, from -$21.25M to $201.19M.
- What is the long-term trend for Alnylam Pharmaceuticals's other comprehensive income (loss)?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's other comprehensive income (loss) has grown at a -23.2% compound annual growth rate (CAGR), from -$842.46M to $292.52M.